Close Menu

This story has been updated to clarify details of Foundation Medicine's FoundationOne CDx. 

CHICAGO – Although NantHealth won US Food and Drug Administration 510(k) clearance last week for its Omics Core whole-exome test for determining tumor mutational burden, the company cannot market it as a test that can predict whether cancer patients will respond to a specific immunotherapy. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.